Detalhe da pesquisa
1.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(1): 77-90, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36493792
2.
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
JAMA
; 323(13): 1266-1276, 2020 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32259228
3.
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Invest New Drugs
; 36(4): 629-637, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29196957
4.
Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
BMC Cancer
; 18(1): 1292, 2018 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30591028
5.
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Lancet
; 388(10043): 488-97, 2016 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27291997
6.
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
NPJ Breast Cancer
; 10(1): 34, 2024 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38671001
7.
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
J Clin Oncol
; 42(9): 987-993, 2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194616
8.
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
Ther Adv Med Oncol
; 15: 17588359231151840, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36756142
9.
Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial.
Clin Cancer Res
; 27(14): 3861-3866, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33632930
10.
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Cancer Med
; 10(3): 843-856, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33474828
11.
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
Cancer Med
; 9(3): 882-893, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31821732
12.
Incidence and Management of Olaratumab Infusion-Related Reactions.
J Oncol Pract
; 15(11): e925-e933, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31268811
13.
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Eur J Cancer
; 107: 186-195, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30573277
14.
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
Lung Cancer
; 111: 108-115, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28838379
15.
Mechanical bridge to recovery in pheochromocytoma myocarditis.
Nat Rev Cardiol
; 6(7): 482-7, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19554007